PDF(Pubmed)
Abstract：
UNASSIGNED: No specific data have been systematically collected regarding lymphoma patient characteristics, while non-Hodgkin lymphoma (NHL) is identified as the 7th most common cancer and Hodgkin lymphoma (HL) is the 28th. Inflammation plays an important role in the pathogenesis and progression of lymphoma. Malnutrition is an adverse prognostic factor in lymphoma. Systemic Inflammatory Index (SII), Prognostic Nutritional Index (PNI), and Advanced Lung Cancer Inflammation Index (ALI) were biomarkers depicting inflammation and nutritional status. This study aims to describe the clinical and biomarker characteristics of both HL and NHL patients.
UNASSIGNED: This descriptive study used a cross-sectional design, and data were collected from Hasan Sadikin Hospital lymphoma registry from January 2020 to November 2023. Demographic, staging, and histopathological data were extracted. Three biomarkers were evaluated. Survival curves were drawn using Kaplan-Meier curve analysis, and the log rank test was used for comparison of survival between early and advanced stage.
UNASSIGNED: A total of 271 patients were recruited as participants, and the majority (80.5%) had NHL, with diffuse large B-cell lymphoma (DLBCL) being the most common histopathological type (50.5%). Early disease was observed in two-thirds of patients, and low-risk International Prognostic Index (IPI) score was the most common prognostic score found (95%). SII was slightly higher in early compared to advanced stages. Treatment response was evaluated from 101 patients, and complete response was observed in 44.5%. Two-year overall survival (OS) was 93.1%, with median survival 22.7 (95% CI 21.9-23.5) months. In early stage, the median survival was slightly longer than in advanced stage [23.0 (95% CI 22.2-23.8) vs 21.6 (95% CI 19.3-23.8) months, P=0.09].
UNASSIGNED: Hodgkin lymphoma and DLBCL had similar clinical and biomarker characteristics. There were slight differences between the three biomarkers SII, ALI, and PNI based on the disease stage. Almost all patients still survived at 2-year follow-up.
UNASSIGNED: This descriptive study used a cross-sectional design, and data were collected from Hasan Sadikin Hospital lymphoma registry from January 2020 to November 2023. Demographic, staging, and histopathological data were extracted. Three biomarkers were evaluated. Survival curves were drawn using Kaplan-Meier curve analysis, and the log rank test was used for comparison of survival between early and advanced stage.
UNASSIGNED: A total of 271 patients were recruited as participants, and the majority (80.5%) had NHL, with diffuse large B-cell lymphoma (DLBCL) being the most common histopathological type (50.5%). Early disease was observed in two-thirds of patients, and low-risk International Prognostic Index (IPI) score was the most common prognostic score found (95%). SII was slightly higher in early compared to advanced stages. Treatment response was evaluated from 101 patients, and complete response was observed in 44.5%. Two-year overall survival (OS) was 93.1%, with median survival 22.7 (95% CI 21.9-23.5) months. In early stage, the median survival was slightly longer than in advanced stage [23.0 (95% CI 22.2-23.8) vs 21.6 (95% CI 19.3-23.8) months, P=0.09].
UNASSIGNED: Hodgkin lymphoma and DLBCL had similar clinical and biomarker characteristics. There were slight differences between the three biomarkers SII, ALI, and PNI based on the disease stage. Almost all patients still survived at 2-year follow-up.
摘要：
■尚未系统地收集有关淋巴瘤患者特征的具体数据，而非霍奇金淋巴瘤（NHL）被确定为第7位最常见的癌症，霍奇金淋巴瘤（HL）是第28位。炎症在淋巴瘤的发病和进展中起着重要作用。营养不良是淋巴瘤的不良预后因素。全身炎症指数（SII），预后营养指数（PNI），和晚期肺癌炎症指数（ALI）是描述炎症和营养状况的生物标志物。本研究旨在描述HL和NHL患者的临床和生物标志物特征。
■这项描述性研究使用了横截面设计，数据来自2020年1月至2023年11月HasanSadikin医院淋巴瘤登记处。人口统计,分期,并提取组织病理学数据。评估了三种生物标志物。使用Kaplan-Meier曲线分析绘制生存曲线，采用对数秩检验比较早期和晚期的生存率。
■共招募了271名患者作为参与者，大多数（80.5%）患有NHL，弥漫性大B细胞淋巴瘤（DLBCL）是最常见的组织病理学类型（50.5%）。在三分之二的患者中观察到早期疾病，低危国际预后指数(IPI)评分是最常见的预后评分(95%).与晚期相比，早期的SII略高。对101例患者的治疗反应进行了评估，并观察到44.5％的完全缓解。2年总生存率（OS）为93.1%，中位生存期为22.7个月（95%CI21.9-23.5个月）。在早期阶段,中位生存期略长于晚期[23.0(95%CI22.2-23.8)vs21.6(95%CI19.3-23.8)个月,P=0.09]。
■霍奇金淋巴瘤和DLBCL具有相似的临床和生物标志物特征。三种生物标志物SII之间有轻微差异，ALI,和基于疾病阶段的PNI。几乎所有患者在2年的随访中仍然存活。
■这项描述性研究使用了横截面设计，数据来自2020年1月至2023年11月HasanSadikin医院淋巴瘤登记处。人口统计,分期,并提取组织病理学数据。评估了三种生物标志物。使用Kaplan-Meier曲线分析绘制生存曲线，采用对数秩检验比较早期和晚期的生存率。
■共招募了271名患者作为参与者，大多数（80.5%）患有NHL，弥漫性大B细胞淋巴瘤（DLBCL）是最常见的组织病理学类型（50.5%）。在三分之二的患者中观察到早期疾病，低危国际预后指数(IPI)评分是最常见的预后评分(95%).与晚期相比，早期的SII略高。对101例患者的治疗反应进行了评估，并观察到44.5％的完全缓解。2年总生存率（OS）为93.1%，中位生存期为22.7个月（95%CI21.9-23.5个月）。在早期阶段,中位生存期略长于晚期[23.0(95%CI22.2-23.8)vs21.6(95%CI19.3-23.8)个月,P=0.09]。
■霍奇金淋巴瘤和DLBCL具有相似的临床和生物标志物特征。三种生物标志物SII之间有轻微差异，ALI,和基于疾病阶段的PNI。几乎所有患者在2年的随访中仍然存活。
